HOME >> BIOLOGY >> NEWS
Hormone found to reduce appetite by a third

An international team of scientists has discovered a hormone that can significantly decrease the appetite, reducing the amount of food eaten in a day by a third.

The research, published today in Nature, shows how scientists from Imperial College London, with assistance from Oregon Health and Sciences University, USA, and the Garvan Institute of Medical Research, Australia, discovered the novel action of hormone PYY3-36.

PYY3-36 is normally released from the gastro-intestinal tract after eating, in proportion to calorific meal content, telling the brain the body is no longer hungry. When a group of volunteers received artificial infusions of the hormone at normal post-feeding concentrations, their food intake was reduced by a third for a day.

Professor Stephen Bloom, from Imperial College London at the Hammersmith Hospital, comments: "The discovery that PYY3-36 suppresses appetite could be of huge benefit to those struggling with weight problems. With over a billion people across the world now extremely overweight, it is vital this problem is tackled.

"It may be possible to identify foods which cause the release of more PYY3-36, helping to naturally limit appetite, or it may be possible to create a tablet with a similar effect, providing an excellent, natural and safe long term treatment for obesity."

The research was undertaken as part of an ongoing programme at Imperial, looking into how human drives work, of which appetite is an important example.

To test if PYY3-36 is effective, twelve volunteers were infused with either PYY3-36 or saline for ninety minutes in a double blind randomised crossover trial at Hammersmith Hospital, London. Two hours later, the volunteers were offered an unlimited buffet meal.

In the group receiving PYY3-36, average calorific intake dropped by a third over the next 24 hours.

The researchers also looked at how hungry the test group felt both during and after transfusio
'"/>

Contact: Tony Stephenson
at.stephenson@ic.ac.uk
020-7594-6712
Imperial College London
7-Aug-2002


Page: 1 2

Related biology news :

1. Hormone helps fish to mate, may affect human hearing
2. Hormone linked to obesity plays positive role in fertility & possibly male arousal
3. Hormones, sand & terrorism
4. Hormone therapy could help prevent pre-term births
5. Hormones modify the type of proteins produced
6. Hormone replacement therapy may improve breast cancer detection and survival rate
7. Hormone replacement therapy may help prevent heart vessel disease, says Wake Forest researcher
8. Hormone replacement therapy may help prevent chronic wounds in elderly patients
9. Hormone therapy may boost quality of life, say Stanford researchers
10. APS hosts the "Genome and Hormone" Conference
11. Hormone the trigger for fat metabolism; scientists closer to tests in humans

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Hormone found reduce appetite third

(Date:12/11/2014)... 2014  Data Sciences International (DSI), the global ... new series of digital telemetry implants to meet ... series, part of the PhysioTel™ Digital platform, was ... physiologic data when incorporating functional endpoints into repeat-dose ... toxicology studies has evolved from short ECG strips ...
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/5/2014)... -- Tute Genomics, a leader in cloud-based solutions for genome ... led by UK-based Eurovestech. Peak Ventures and a number ... "We are at a pivotal time in ... seeks new approaches for the diagnosis, treatment and prevention ... and CEO of Tute Genomics. "One of the main ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: